IRME (IR-Med) YoY EBITDA Growth: 20.00% (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is IR-Med YoY EBITDA Growth?

IR-Med IRME +90.91% YoY EBITDA Growth is 20.00% as of Jun. 2025.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. IR-Med's YoY EBITDA Growth for the quarter that ended in Jun. 2025 was 20.00%.

IR-Med's EBITDA per Share for the three months ended in Jun. 2025 was $-0.00.

IR-Med YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for IR-Med's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IR-Med YoY EBITDA Growth Chart

IR-Med Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
YoY EBITDA Growth
0.00 -436.36 -18.64 -1.43 61.97

IR-Med Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 68.75 52.94 72.22 55.56 20.00

IR-Med YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

IR-Med's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (A: Dec. 2024 )
=(EBITDA per Share (A: Dec. 2024 )-EBITDA per Share (A: Dec. 2023 ))/ | EBITDA per Share (A: Dec. 2023 ) |
=(-0.027--0.071)/ | -0.071 |
=61.97 %

IR-Med's YoY EBITDA Growth for the quarter that ended in Jun. 2025 is calculated as:

YoY EBITDA Growth (Q: Jun. 2025 )
=(EBITDA per Share (Q: Jun. 2025 )-EBITDA per Share (Q: Jun. 2024 )) / | EBITDA per Share (Q: Jun. 2024 )) |
=(-0.004--0.005)/ | -0.005 |
=20.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 20.00% mean?
IR-Med (IRME) has a YoY EBITDA Growth of 20.00% as of Jun. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for IR-Med and its competitors.
Is IR-Med's YoY EBITDA Growth too high?
IR-Med's current YoY EBITDA Growth is 20.00%.
How does IR-Med's YoY EBITDA Growth compare to SSKN and NUMD?
IR-Med's YoY EBITDA Growth of 20.00% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Devices & Instruments company?
A good YoY EBITDA Growth depends on the Medical Devices & Instruments industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for IR-Med and its competitors. IR-Med's current YoY EBITDA Growth is 20.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IR-Med stock overvalued right now?
IR-Med (IRME) has a current YoY EBITDA Growth of 20.00%. The current YoY EBITDA Growth is 20.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For IR-Med (IRME), the current YoY EBITDA Growth is 20.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

IR-Med Business Description

Address Z.H.R Industrial Zone, P.O. Box 143, Rosh Pina, ISR, 1231400
IR-Med Inc is a development-stage medical device company that is developing its technology through its Subsidiary and utilizing Infra-Red-light spectroscopy (IR) combined with Artificial Intelligence (AI) technology to develop non-invasive devices for various medical indications. These devices detect and measure biomarkers and molecules in blood and human tissue in real-time.